BACKGROUND: Current first-line treatments for metastatic renal cell carcinoma (mRCC) include the multityrosine kinase inhibitors pazopanib and sunitinib. Both agents had similar progression-free survival (PFS) and overall survival (OS) in the COMPARZ trial (Comparing the Efficacy, Safety and Tolerability of Pazopanib versus Sunitinib); however, the adverse event profiles of the 2 agents are different. In the PISCES trial (Patient Preference Study of Pazopanib versus Sunitinib in Advanced or Metastatic Kidney Cancer), patients and physicians preferred pazopanib primarily because it offered better health-related quality of life (HRQoL) and caused less fatigue.
R enal cell carcinoma (RCC) represents approximately 85% of all renal cancers. 1 In the United States, an estimated 63,920 individuals are expected to be diagnosed with cancer of the kidney and renal pelvis in 2014, and an estimated 13,680 are projected to die from this cancer. 2 Approximately 17% of patients with RCC present with metastases at diagnosis and have a 5-year relative survival of only 12.3%.
RCC does not respond well to chemotherapy. Immunotherapy such as interferon-alpha (IFN-α) has the twin drawbacks of significant toxicity and lack of effectiveness. 3, 4 High-dose interleukin-2 (IL-2) has been shown to achieve long-lasting responses in a small subset of patients but is also associated with significant toxicity, and an overall survival (OS) advantage has not been conclusively demonstrated. 5, 6 Targeted therapies approved for the treatment of patients with advanced RCC, such as the vascular endothelial growth factor inhibitors sorafenib, bevacizumab, sunitinib, and pazopanib, as well as the mammalian target of rapamycin inhibitors temsirolimus 7 and everolimus, 8 • Pazopanib has been directly compared with sunitinib in 2 phase III randomized trials in patients with advanced/metastatic renal cell carcinoma (mRCC) who had not received prior treatment.
• Results of the COMPARZ trial (Comparing the Efficacy, Safety and Tolerability of Pazopanib versus Sunitinib), a randomized, open-label, parallel-group study, demonstrated the noninferiority of pazopanib compared with sunitinib with regard to progression-free survival.
• The PISCES trial (Patient Preference Study of Pazopanib versus
Sunitinib in Advanced or Metastatic Kidney Cancer), a doubleblind, crossover study that assessed patients' preferences for pazopanib versus sunitinib, showed that both patients and physicians preferred pazopanib to sunitinib primarily because it offered better health-related quality of life and caused less fatigue.
What is already known about this subject
• This study compares the incremental cost-effectiveness of pazopanib versus sunitinib from a U.S. health care perspective.
• Results of this study suggest that pazopanib is cost-effective compared with sunitinib as the first-line treatment of patients with mRCC in the United States.
What this study adds
receiving pazopanib had statistically significantly better scores in 11 of 14 health-related quality-of-life (HRQoL) comparisons 15 and had nominally lower rates of nonstudy medical resource utilization (MRU) compared with patients receiving sunitinib during the first 6 months of treatment.
The PISCES trial (Patient Preference Study of Pazopanib versus Sunitinib in Advanced or Metastatic Kidney Cancer; ClinicalTrials.gov identifier: NCT01064310) was a doubleblind, crossover study that assessed patients' preferences for pazopanib versus sunitinib. 16 Patients were randomized to receive pazopanib or sunitinib for 10 weeks of treatment in period 1, followed by a 2-week washout period, then 10 additional weeks of treatment with the alternative therapy in period 2. Results showed that patients and physicians preferred pazopanib primarily because it offered better HRQoL and caused less fatigue. 16, 17 The PISCES trial was not designed to measure or compare the clinical efficacy of either pazopanib or sunitinib.
have demonstrated improved progression-free survival (PFS) compared with immunotherapy or placebo in both the firstline and/or second-line settings. 3, [9] [10] Sunitinib (Sutent, Pfizer) is administered orally as 50 milligrams (mg) once daily in a 4-week-on/2-week-off schedule. 10 Pazopanib (Votrient, GlaxoSmithKline) is administered at a dose of 800 mg given orally once daily. 9 Both drugs have similar mechanisms of action and have demonstrated efficacy in separate phase III trials with differences in the adverse event (AE) profiles. [11] [12] [13] [14] Pazopanib has been directly compared with sunitinib in 2 phase III randomized trials in patients with advanced/metastatic renal cell carcinoma (mRCC) who had not received prior treatment. The 
Model Inputs
The objective of this study was to compare the cost-effectiveness of pazopanib versus sunitinib as the first-line treatment of patients with mRCC from a U.S. health care system perspective based on results from the COMPARZ and PISCES trials.
■■ Methods Overview
A partitioned-survival analysis model with 3 health statesalive with no progression (preprogression), alive with progression (postprogression), and dead-was used to calculate the expected costs, life-years, and quality-adjusted life-years (QALYs) for patients receiving pazopanib and sunitinib as the first-line treatment for mRCC. The population of interest was treatment-naïve patients with mRCC. The only comparators of interest were pazopanib and sunitinib. Although sorafenib, bevacizumab (in combination with IFN-α), and temsirolimus are also approved for use in the United States and European Union as first-line treatments of advanced/mRCC, comparisons with these agents would have required an indirect treatment comparison, which represents a lower level of evidence than the direct comparison examined in the COMPARZ trial. A U.S. health care system perspective was employed. Only direct medical costs associated with pazopanib and sunitinib treatment were considered. All cost estimates were in 2013 U.S. dollars. 18 The time horizon of the analysis was 37.5 months (163 weeks), consistent with the latest time point for which survival time data were available for PFS and OS in both groups of the COMPARZ trial as of May 21, 2012 , the data cut-off date. Sensitivity analyses were conducted using a 10-year time horizon.
In the model, the proportion of patients in each health state over time was calculated based on survival functions for PFS and OS. Postprogression survival (PPS) was calculated as the difference between OS and PFS. Costs and HRQoL were assumed to be conditioned on treatment and expected time in the progression-free and postprogression disease states. The model cycle length was 1 week, which was chosen to accommodate the 4-week treatment cycle for pazopanib and the 6-week treatment cycle for sunitinib and to avoid the need for a half-cycle correction.
The model was used to generate estimates of expected lifetime costs including medication costs, dispensing/administration costs, other costs associated with pazopanib and sunitinib treatment (defined later and outlined in Table 1 ), routine follow-up, monitoring and supportive care costs, and total costs. Preprogression, postprogression, overall life expectancy (i.e., progression-free, postprogression, and overall life-years), and QALYs for pazopanib and sunitinib were also estimated. Effectiveness measures were calculated on undiscounted and discounted bases; costs were calculated on a discounted basis. An annual discount rate of 3% was used. 19 The incremental cost-effectiveness ratio (ICER) for pazopanib versus sunitinib was defined as the ratio of the difference (pazopanib versus sunitinib) in total costs to the difference in QALYs (incremental cost per QALY gained). The net monetary benefit (NMB) of pazopanib versus sunitinib was also calculated for different levels of the threshold value of cost-effectiveness ($50,000, $100,000, and $200,000 per QALY gained). 
Survival Distributions for PFS and OS Used in the Model

Model Estimation
Model inputs are summarized in Table 1 . Survival functions out to 37.5 months for PFS and OS were estimated based on Kaplan-Meier (KM) survival distributions from the COMPARZ trial ( Figure 1 ). For sensitivity analyses using a 10-year time frame, PFS and OS beyond 37.5 months were based on Weibull survival functions fit to individual patient data from the COMPARZ trial using accelerated failure time regression. Investigator-assessed PFS, rather than independent review committee (IRC)-assessed PFS, was used because the former is more likely to accurately reflect assessment of disease progression during the course of routine clinical practice. Also, IRC-assessed PFS may introduce bias because of informative censoring of nonconfirmed locally determined progressions. 21 The COMPARZ trial did not include a preference-based assessment of HRQoL. In the PISCES trial, the EuroQol 5-dimension (EQ-5D) questionnaire, a preference-based measure of HRQoL, was administered at baseline, the end of the 2-week washout period, and week 10 of the second treatment period. 16 Utility values for the PFS state for pazopanib and sunitinib were therefore estimated based on EQ-5D data from the PISCES trial. 17 For pazopanib, the utility value at week 10 of period 2 for the sunitinib-pazopanib group was used. For sunitinib, a weighted average of the mean (standard error [SE] ) utility value at week 10 of the second treatment period for the pazopanib-sunitinib group (0.6325 [0.043]) and the utility value during the washout period for the sunitinib-pazopanib group was used (0.8103 [0.029]). The former reflects utility during the sunitinib on-treatment period, and the latter reflects utility during the sunitinib off-treatment period. The weights (66.6% and 33.3%, respectively) were calculated to reflect the relative duration of the sunitinib on-and off-treatment periods (i.e., 28/42 days and 14/42 days, respectively). Because patients were not followed after progression in the PISCES trial, the utility value for the postprogression state was assumed to be the same for pazopanib and sunitinib and was estimated based on the mean EQ-5D utility value after termination of secondline therapy in the sunitinib phase III trial. 22 Unit costs of pazopanib and sunitinib were based on published wholesale acquisition costs (WAC) that reflect manufacturer list prices. 23 Pazopanib and sunitinib were assumed to be dispensed every 4 and 6 weeks, respectively. In calculating medication costs, it was assumed that any medication supplied but not taken was discarded (i.e., the cost of a full prescription was incurred on the first day of each treatment cycle). Patients were assumed to require a single visit per cycle for administration of oral therapy at a cost of $75.77 per visit based on the national average Medicare fee for an office visit (Current Procedural Terminology, 4th edition (CPT-4) 99214: Office evaluation and management involving decision making of moderate complexity). 24 The cost of dispensing each prescription was assumed to be $10.50. 25 Based on these prices and planned dosages, the average cost per 6 weeks of therapy was estimated to be $9,983 for pazopanib and $10,762 for sunitinib. Medication costs were adjusted for dose intensity using the ratio of the mean actual dose versus the mean planned cumulative dose-over all days of follow-up-of pazopanib (68%) and sunitinib (67%) in the COMPARZ trial. Dispensing costs were adjusted by the ratio of the mean actual versus mean planned cumulative number of cycles with pazopanib (78%) and sunitinib (79%) in the COMPARZ trial. These adjustments account for dose reductions, treatment interruptions, and treatment discontinuation before and/or after disease progression.
Other costs associated with pazopanib and sunitinib treatment were estimated by combining monthly rates of nonstudy MRU from the COMPARZ trial with unit cost estimates from published or publically available sources. 26 Costs of nonstudy medical office visits, laboratory visits and tests, radiological visits and tests, home health visits, hospital days (general ward or intensive care unit), and emergency department visits were assumed to be incurred each month until progression. These cost differences were not assessed for statistical significance.
The estimated cost of a day in the general ward was based on the per diem cost of hospitalizations with a primary diagnosis International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code of 189.0-malignant neoplasm of kidney except renal pelvis-and with a nonsurgical principal procedure from the Healthcare Costs and Utilization Project National Inpatient Sample database. 27 The estimated cost of a day in the intensive care unit was taken from a 2010 retrospective analysis of critical care costs using Medicare hospital cost reports. 28 Costs of primary care physician; nurse practitioner/physician's assistant/nurse; and specialist visits, telephone consultations, and radiological tests were taken from the 2013 Medicare Physician Fee Schedule. 25 Costs of all primary care and specialist visits were assumed to correspond to CPT-4 code 99214-an office visit involving decision making of moderate complexity. Nurse practitioner/physician's assistant/nurse visits were assigned the costs of CPT-4 99211 (an outpatient visit that may not require the presence of a physician, presenting problems are minimal); telephone consultations were assigned the cost of CPT-4 99212 (an office visit involving straightforward decision making). Costs of emergency department visits were from a 2005 study that used hospital discharge reports to estimate the cost of an emergency department visit. 29 Costs of laboratory services were from the 2013 Medicare Clinical Laboratory Fee Schedule. 30 The costs of positron emission tomography (PET) and PET/computed tomography scans were based on the costs of CPT-4 78811 (tumor imaging using PET over a limited area) as reported in a General Electric Healthcare publication, which provides the 2013 national Medicare physician fee schedule and facility payment rates for such scans. 31 The costs of "other" nonspe-cific services or tests were assigned the average cost of related specific services or tests. Unit cost estimates for all services are provided in the Appendix (available in online article). Combining treatment group-specific estimates of mean (SE) nonstudy MRU from the COMPARZ trial and the unit cost estimates just described, the mean (SE) monthly costs of nonstudy MRU associated with pazopanib and sunitinib were estimated to be $684.53 ($78.54) and $913.18 ($89.09), respectively, implying a difference of $228.65 per month for sunitinib versus pazopanib. Costs were not assigned to specific AEs, since it was assumed that the costs of nonstudy MRU reflected any differences between pazopanib and sunitinib in efficacy and safety. Routine follow-up, progression, and supportive care costs were obtained from an economic evaluation of sunitinib for the first-line treatment of mRCC. 32 The costs of post-treatment anticancer therapy (PTACT) for pazopanib and sunitinib were included in a sensitivity analyses and were estimated based on utilization data in the COMPARZ trial and published list prices.
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Analyses Probabilistic Sensitivity Analyses. Probabilistic sensitivity analyses were conducted by simultaneously sampling from estimated probability distributions of model parameters to obtain 1,000 sets of model input estimates. 33, 34 PFS and OS were sampled from bootstrapped KM survival distributions. For sampled distributions of PFS and OS where the maximum follow-up was less than 37.5 months, PFS and OS from the end of follow-up to 37.5 months were estimated by extrapolation using Weibull distributions fitted to the data from the corresponding bootstrap sample. The utility for PFS was assumed to be distributed as a beta random variable. The decrement in utility for PPS versus PFS was assumed to be distributed as a normal random variable. Unit costs of medications, dispensing, and administration were not sampled. Costs of routine follow-up, progression, and terminal phase were assumed to be distributed as lognormal random variables with SEs assumed to be 0.25 times the base-case estimate. Costs of nonstudy MRU from the COMPARZ trial were distributed as log-normal variables. For each simulation, calculations were performed to derive the expected costs and QALYs for pazopanib and sunitinib; differences in expected costs and QALYs between pazopanib and sunitinib; and the incremental cost per QALY gained with pazopanib versus sunitinib. For expected costs and QALYs and the differences in expected costs and QALYs, 95% confidence intervals (CIs) were calculated based on the 2.5 and 97.5 percentiles of these simulations. Simulation results were plotted on a cost-effectiveness plane for each comparison, and cost-effectiveness acceptability curves were constructed for pazopanib versus sunitinib to identify the proportion of simulations for which pazopanib was 
Based on medical resource utilization data from the Comparing the Efficacy, Safety and Tolerability of Pazopanib versus Sunitinib (COMPARZ) study. NMB = net monetary benefit; QALY = quality-adjusted life-year.
TABLE 2
Base-Case Results was 0.088 (95% CI = −0.128-0.286). At a threshold value of cost-effectiveness of $100,000 per QALY gained, the median NMB for pazopanib versus sunitinib was $16,027 (95% CI = −$3,614-$36,302). In 69% of the simulations, pazopanib was projected to yield more QALYs and lower costs compared with sunitinib (pazopanib is dominant). Pazopanib was projected to yield higher costs and lower QALYs (sunitinib is dominant) in 1% of the simulations. Pazopanib was projected to yield more QALYs in 79% of the simulations and lower costs in 89% of the simulations.
Acceptability curves for pazopanib and sunitinib are shown in Figure 2B . The probability that pazopanib is cost-effective versus sunitinib was estimated to be 97% for a threshold value of cost-effectiveness of $50,000 per QALY gained; 94% for a threshold value of cost-effectiveness of $100,000 per QALY gained; and 88% for a threshold value of cost-effectiveness of $200,000 per QALY gained. The probability that pazopanib is cost-effective versus sunitinib was estimated to be 90% or more for cost-effectiveness thresholds between $10,000 and $160,000 per QALY gained. In deterministic sensitivity analyses (NMB calculated using a threshold value of $100,000 per QALY), the NMB for pazopanib versus sunitinib was estimated to range from $8,292 to $20,933. NMB was most sensitive to assumptions regarding costs associated with pazopanib and sunitinib treatment and the utility values for sunitinib and pazopanib (Figure 3) . NMB was more favorable when the costs of PTACT were included and when a 10-year time horizon was used and less favorable when the utility values for sunitinib were assumed to be the same as those for pazopanib. The NMB of pazopanib versus sunitinib was positive in all scenarios examined. preferred given various levels of decision makers' threshold values for cost per QALY gained.
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Deterministic Sensitivity Analyses. Deterministic sensitivity analyses were conducted to explore the impact of changing key parameter values on the ICER and NMB of pazopanib versus sunitinib. A variety of scenarios were evaluated encompassing the following parameters: time horizon, PFS, OS, relative dose intensity, administration/dispensing costs, monthly costs, decrements in utility, and discount rates. When calculating NMB in deterministic sensitivity analyses, the threshold value for cost-effectiveness was defined as $100,000 per QALY.
No institutional review board approval was performed, since this study was a post hoc cost-effectiveness analysis of a previously approved clinical trial using de-identified records.
■■ Results
Because pazopanib was estimated to provide more QALYs at a lower cost compared with sunitinib, it was dominant compared with sunitinib in the base case ( Table 2 ). The NMB of pazopanib versus sunitinib was $11,343, $15,857, and $24,886 at threshold values of cost-effectiveness of $50,000, $100,000, and $200,000 per QALY gained, respectively. At a threshold value of $100,000 per QALY gained, 43% of the NMB was due to reduced costs (savings of $6,828), and 57% was a consequence of increased QALYs (0.090 QALYs gained "monetized" at a value of $100,000 per QALY equals $9,000).
In the probabilistic sensitivity analyses, the median difference in expected cost for pazopanib versus sunitinib was −$7,078 (95% CI = −$18,771-$4,394; Figure 2A ). The median difference in expected QALYs for pazopanib versus sunitinib 
■■ Discussion
This study evaluated the cost-effectiveness of pazopanib versus sunitinib as the first-line treatment for mRCC from a U.S. health care system perspective. Using PFS, OS, and MRU data from the COMPARZ study; utilities data from the PISCES trial; and published cost estimates, pazopanib was projected to yield more QALYs at a lower cost compared with sunitinib. Therefore, pazopanib was estimated to be dominant compared with sunitinib in the base case. At a cost-effectiveness threshold value of $100,000 per QALY gained, the NMB with pazopanib versus sunitinib was estimated to be $15,857. Probabilistic sensitivity analyses showed a 90% or greater probability of pazopanib being cost-effective versus sunitinib for cost-effectiveness threshold values between $10,000 and $160,000 per QALY gained. In all scenarios tested in the deterministic sensitivity analyses, which included decrements in utility values, the NMB of pazopanib versus sunitinib was always positive and favored pazopanib.
The model used in this evaluation was similar to one employed to examine the cost-effectiveness of pazopanib versus best supportive care, IFN-α, and sunitinib as first-line treatment for advanced/mRCC from a United Kingdom National Health Service perspective in the manufacturer's submission to the National Institute for Health and Care Excellence (NICE). 36 In the final analyses performed by the evidence review group (ERG) using the manufacturer's model and assuming a 12.5% discount to the list price for pazopanib, pazopanib was more costly and more effective than sunitinib and had a cost-effectiveness ratio ranging from £1,790 to £5,330 per QALY gained. Given a cost-effectiveness threshold value of £30,000, there was a 54% probability that pazopanib was preferred to sunitinib. However, the results of the comparison of pazopanib and sunitinib reported in the current analysis are associated with substantially less uncertainty than those reported by Kilonzo et al. (2013) , since this study is based on a single, direct comparison of pazopanib and sunitinib, whereas the NICE analyses were based on an indirect treatment comparison of trials of pazopanib versus placebo, IFN versus placebo, and sunitinib versus IFN. 36 Moreover, the trial of pazopanib versus placebo used in Kilonzo et al. was confounded by crossover. 36 The uncertainty in the prior analyses were noted by the ERG and recognized by the Appraisal Committee and were reflected in their positive recommendations for pazopanib contingent on the outcome of the COMPARZ trial.
Limitations
This study has some limitations. First, this study compared pazopanib and sunitinib only and did not evaluate the costeffectiveness of other therapies that may be approved for use as first-line treatment of advanced/mRCC in the United States. Comparisons with these agents would have required an indirect treatment comparison, which represents a lower level of evidence than the direct comparison of pazopanib versus sunitinib in the COMPARZ trial, which was the primary basis of this evaluation.
The estimated benefits of pazopanib on QALYs were derived from the assumed differences in utility values between patients who received pazopanib versus those who received sunitinib. Because the COMPARZ trial did not include a preference-based HRQoL assessment, utility values from the PISCES trial were used in the model. Data from the PISCES trial represent the only data on EQ-5D utilities for pazopanib and sunitinib drawn from a clinical trial. However, because of the design of the study and the way the data from the study were utilized, the differences in utility values for pazopanib and sunitinib used in this analysis were not based on a randomized comparison. Nevertheless, the estimated benefits of pazopanib on HRQoL in the model are consistent with other results of the PISCES and COMPARZ studies with regard to patient preferences and HRQoL. 15, 16 The differences in AEs between treatment groups in the PISCES trial were consistent with those in the COMPARZ trial, supporting the notion that utility values from the PISCES trial likely reflect those that would have been obtained from the COMPARZ trial if utility data had been collected.
The estimated cost savings associated with pazopanib in this analysis are largely due to the assumed lower WAC of pazopanib versus sunitinib, as well as the lower estimated monthly costs of other services related to treatment of mRCC based on MRU data from the COMPARZ trial. The actual prices paid for each drug may differ across payers and health care systems in the United States and may not reflect those used in our analysis. Because COMPARZ was a multinational trial, the MRU in the trial may not reflect utilization in all settings.
■■ Conclusions
The results of this cost-effectiveness analysis based on a survival analysis model employing data from 2 randomized phase III clinical trials comparing pazopanib with sunitinib suggest that pazopanib is cost-effective compared with sunitinib as a first-line treatment of patients with mRCC in the United States.
